292 related articles for article (PubMed ID: 19273405)
1. Body image perceptions in men with prostate cancer.
Harrington JM; Jones EG; Badger T
Oncol Nurs Forum; 2009 Mar; 36(2):167-72. PubMed ID: 19273405
[TBL] [Abstract][Full Text] [Related]
2. Body image and quality of life in men with prostate cancer.
Harrington JM; Badger TA
Cancer Nurs; 2009; 32(2):E1-7. PubMed ID: 19258822
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
4. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Hammett J; Malcolm JB; Judge BA; Womack JH; Kincade MC; Ogles ML; Mancini JG; Patterson AL; Wake RW; Derweesh IH
Can J Urol; 2008 Oct; 15(5):4249-56; discussion 4256. PubMed ID: 18814813
[TBL] [Abstract][Full Text] [Related]
6. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
8. Body image dissatisfaction in cancer survivors.
DeFrank JT; Mehta CC; Stein KD; Baker F
Oncol Nurs Forum; 2007 May; 34(3):E36-41. PubMed ID: 17573320
[TBL] [Abstract][Full Text] [Related]
9. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
Lage MJ; Barber BL; Markus RA
Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
[TBL] [Abstract][Full Text] [Related]
10. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
11. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study.
Pirl WF; Siegel GI; Goode MJ; Smith MR
Psychooncology; 2002; 11(6):518-23. PubMed ID: 12476433
[TBL] [Abstract][Full Text] [Related]
12. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
13. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.
Hansen PA; Dechet CB; Porucznik CA; LaStayo PC
PM R; 2009 Nov; 1(11):1019-24. PubMed ID: 19942188
[TBL] [Abstract][Full Text] [Related]
14. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
[TBL] [Abstract][Full Text] [Related]
15. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
16. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
18. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
[TBL] [Abstract][Full Text] [Related]
19. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy.
Saini A; Berruti A; Cracco C; Sguazzotti E; Porpiglia F; Russo L; Bertaglia V; Picci RL; Negro M; Tosco A; Campagna S; Scarpa RM; Dogliotti L; Furlan PM; Ostacoli L
Urol Oncol; 2013 Apr; 31(3):352-8. PubMed ID: 21803612
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer.
Ott C; Fulton MK
J Am Acad Nurse Pract; 2005 Mar; 17(3):113-22. PubMed ID: 15748224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
